EMEA: Risk Management Plans Should Address Vaccine Concerns

Clinical Trials Advisor
A A
Vaccine safety concerns that emerge before marketing should be investigated during preauthorization and addressed in the manufacturer’s risk management plan (RMP), according to a European Medicines Agency (EMEA) draft guideline.

To View This Article:

Login

Subscribe To Clinical Trials Advisor

Buy This Article Now

Add this article to your cart for $10.00